Home › Funds › Exome Asset Management LLC › MLTX
Exome Asset Management LLC position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Exome Asset Management LLC reported holding 166,493 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$3.2M, representing 2.00% of its reported portfolio and ranking #19 among its reported holdings. Exome Asset Management LLC has disclosed MLTX holdings in 4 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Exome Asset Management LLC's MLTX position evolved
Exome Asset Management LLC first disclosed a stake in MLTX in Q4 2023 at 9,744 shares (US$588K). The position peaked in Q1 2026 at 215,376 shares, worth US$4.0M. Across 4 filings, Exome Asset Management LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 166,493 shares valued at US$3.2M — a reduction of -48,883 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 9.74K | $588.44K | New |
| Q3 2025 | 178.08K | $1.28M | New |
| Q1 2026 | 215.38K | $4.01M | New |
| Q2 2026 | 166.49K | $3.24M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 30 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on Exome Asset Management LLC
FAQ
How long has Exome Asset Management LLC held MLTX?
Exome Asset Management LLC has disclosed MLTX holdings in 4 of the last 11 reported quarters, going back to Q4 2023.
What is Exome Asset Management LLC's current position in MLTX?
As of Q2 2026, Exome Asset Management LLC holds 166.49K shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $3.24M, representing 2.00% of its reported portfolio and ranking #19.
Has Exome Asset Management LLC been buying or selling MLTX?
In the latest 13F filing (Q2 2026), Exome Asset Management LLC reduced its position in MLTX. The position peaked in Q1 2026 at 215.38K shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.